Symbols

CTMX

CytomX Therapeutics·NASDAQ

--(--)

CTMX Profile

Cytomx Therapeutics, Inc.

A leader in the field of conditionally activated oncology therapeutics

Industry

Pharmaceutical

Established Date

Listing Date

10/08/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cytomx.com

Security Type

Common stock

Office address

151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080

Business

Introduction

CytomX Therapeutics, Inc., was incorporated in Delaware in September 2010 and its operations began in 2008. The Company is a clinical-stage, oncology-focused biopharmaceutical company developing innovative therapies based on its proprietary PROBODY technology platform. The platform enables conditionally activated biologics designed to selectively target tumors, and its state-of-the-art clinical program, Varseta-M, is an antibody-drug conjugate in Phase 1 development for colorectal cancer.